Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone650-251-0005
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$387.29 million
Profitability
Miscellaneous
Employees804
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable
Nevro (NYSE:NVRO) Frequently Asked Questions
What is Nevro's stock symbol?
Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."
How were Nevro's earnings last quarter?
Nevro Corp (NYSE:NVRO) posted its earnings results on Thursday, May, 9th. The medical equipment provider reported ($1.45) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.66) by $0.79. The medical equipment provider had revenue of $82.10 million for the quarter, compared to analysts' expectations of $87.47 million. Nevro had a negative return on equity of 31.84% and a negative net margin of 19.79%. Nevro's quarterly revenue was down 6.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.59) earnings per share. View Nevro's Earnings History.
When is Nevro's next earnings date?
What price target have analysts set for NVRO?
11 equities research analysts have issued 1 year price targets for Nevro's stock. Their forecasts range from $35.00 to $90.00. On average, they expect Nevro's stock price to reach $59.3636 in the next twelve months. This suggests a possible upside of 0.5% from the stock's current price. View Analyst Price Targets for Nevro.
What is the consensus analysts' recommendation for Nevro?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 2 sell ratings, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nevro.
What are Wall Street analysts saying about Nevro stock?
Here are some recent quotes from research analysts about Nevro stock:
- 1. According to Zacks Investment Research, "Nevro exited the first quarter on a weak note. However, an increase in R&D expenses in the quarter reflects focus on innovation. Management is optimistic about the long-term prospects of the Senza II platform, launched in late 2018. Nevro is also on track to launch its next product platform, Omnia, which is expected to lend the company a competitive edge in the near future. On the flip side, in the first quarter, the company’s domestic and international revenues deteriorated and loss per share widened on a year-over-year basis. Significant contraction in gross and a surge in operating expenses add to the woes. The stock has underperformed the industry in a year’s time and is also overvalued at the moment." (5/14/2019)
- 2. Northland Securities analysts commented, "We are introducing our FY20 numbers, and our rating / PT remains the same." (1/11/2019)
Has Nevro been receiving favorable news coverage?
News coverage about NVRO stock has trended positive on Sunday, according to InfoTrie. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nevro earned a news impact score of 2.5 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of Nevro's key competitors?
Some companies that are related to Nevro include Hill-Rom (HRC), Insulet (PODD), Haemonetics (HAE), Novocure (NVCR), Penumbra (PEN), ICU Medical (ICUI), Integra Lifesciences (IART), Globus Medical (GMED), Tandem Diabetes Care (TNDM), NuVasive (NUVA), Merit Medical Systems (MMSI), Cantel Medical (CMD), Glaukos (GKOS), Atrion (ATRI) and Irhythm Technologies (IRTC).
What other stocks do shareholders of Nevro own?
Who are Nevro's key executives?
Nevro's management team includes the folowing people:
- Mr. Andrew H. Galligan, Chief Financial Officer (Age 63)
- Mr. Patrick Schmitz, VP of Operations (Age 59)
- Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 45)
- Mr. Doug Alleavitch, VP of Quality (Age 58)
- Mr. D. Keith Grossman, Pres, CEO & Director (Age 59)
Who are Nevro's major shareholders?
Nevro's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.39%), ArrowMark Colorado Holdings LLC (6.17%), Broadfin Capital LLC (2.04%), Perceptive Advisors LLC (1.37%), Perceptive Advisors LLC (1.37%) and Spark Investment Management LLC (1.32%). Company insiders that own Nevro stock include Andrew H Galligan, Michael F Demane and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.
Which institutional investors are selling Nevro stock?
NVRO stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, BlackRock Inc., The Manufacturers Life Insurance Company , Wells Fargo & Company MN, SG Americas Securities LLC, Marshall Wace LLP, Los Angeles Capital Management & Equity Research Inc. and Blair William & Co. IL. View Insider Buying and Selling for Nevro.
Which institutional investors are buying Nevro stock?
NVRO stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Spark Investment Management LLC, Renaissance Technologies LLC, Viking Global Investors LP, ArrowMark Colorado Holdings LLC, Frontier Capital Management Co. LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Nevro.
How do I buy shares of Nevro?
Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nevro's stock price today?
One share of NVRO stock can currently be purchased for approximately $59.05.
How big of a company is Nevro?
Nevro has a market capitalization of $1.80 billion and generates $387.29 million in revenue each year. The medical equipment provider earns $-49,210,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Nevro employs 804 workers across the globe.
What is Nevro's official website?
How can I contact Nevro?
Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]
MarketBeat Community Rating for Nevro (NYSE NVRO)
MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
